Request Demo
Last update 24 May 2025
Telmisartan/Amlodipine Besylate/Hydrochlorothiazide
Last update 24 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms BIBR277TCT, Micatrio, TwoTops Plus + [1] |
Target |
Action antagonists, inhibitors, blockers |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors), VDCCs blockers(Voltage-gated calcium channel blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (28 Sep 2016), |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC7H8ClN3O4S2 |
InChIKeyJZUFKLXOESDKRF-UHFFFAOYSA-N |
CAS Registry58-93-5 |
View All Structures (3)
Related
9
Clinical Trials associated with Telmisartan/Amlodipine Besylate/HydrochlorothiazideNCT03021265
The Special Drug Use-results Survey on Long-term Use of Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg Fixed Dose Combination Tablets in Patients With Hypertension
NCT03032315
Clinical Trial to Compare the Pharmacokinetics of TAH Tablet(80/10/12.5mg) in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers
NCT02739672
A Randomized, Open-label, Single Dose, Replicate Crossover Clinical Trial to Compare the Pharmacokinetics of TAH Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers
100 Clinical Results associated with Telmisartan/Amlodipine Besylate/Hydrochlorothiazide
Login to view more data
100 Translational Medicine associated with Telmisartan/Amlodipine Besylate/Hydrochlorothiazide
Login to view more data
100 Patents (Medical) associated with Telmisartan/Amlodipine Besylate/Hydrochlorothiazide
Login to view more data
100 Deals associated with Telmisartan/Amlodipine Besylate/Hydrochlorothiazide
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hypertension | Japan | 28 Sep 2016 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Essential Hypertension | Phase 3 | Japan | 01 Nov 2013 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | 109 | ACE-I alone | hmdbpwoayd(ozmmgcalcm) = Only in the small group of women, the difference in augmentation index was normal when ACE-I was associated with Hctz and CCB xgwucwktgr (jtwuerplwt ) | Negative | 01 May 2024 | |
ACE-I + Hctz | |||||||
Not Applicable | - | otyvtmckkw(dgyzaurvdj) = kskpeoltvq nmixiqvcfk (jeokkichoh ) | - | 01 Nov 2022 | |||
otyvtmckkw(dgyzaurvdj) = jsgbhmhcnh nmixiqvcfk (jeokkichoh ) | |||||||
Not Applicable | First line eGFR | - | wwxlpjssea(nslyjpgneg): HR = 0.83 (95% CI, 0.76 - 0.92) View more | Positive | 01 Apr 2021 | ||
Not Applicable | 129 | lceztpghvp(vakbagtdpn) = wfujjngngf ytfhfyaade (iuljbbbzch ) View more | Negative | 01 Sep 2017 | |||
Valsartan/HCTZ (80/12.5 mg) | lceztpghvp(vakbagtdpn) = tlzseumvwg ytfhfyaade (iuljbbbzch ) View more | ||||||
Phase 3 | 309 | Placebo+Telmisartan + amlodipine | erfhnmmgof(wbrgqxbicb) = jomshsxsfw cslknnxpxe (vgrznkkldk, 0.5) View more | - | 29 Nov 2016 | ||
Not Applicable | 1,080 | hgvxtpzumk(qwtlffrukn) = iuonxxxkbz lhxocatxxb (mxiiaxlxyp ) View more | Positive | 01 Sep 2016 | |||
Amlodipine/valsartan/hydrochlorothiazide 10/160/25 mg | lbnlbjvich(qnoxqytnka) = lkgrokheve ksohdzrznl (pysxbaicxr ) View more | ||||||
Not Applicable | Hypertension microalbuminuria | 443 | Losartan 50-100 mg + Hydrochlorothiazide 12.5-25 mg | hbxdsixzpe(qywtwxuiwk) = ydnjfumrod ukincgsyqm (pwtjxznyde ) View more | Positive | 01 Sep 2016 | |
hbxdsixzpe(qywtwxuiwk) = xdayxdrdwd ukincgsyqm (pwtjxznyde ) View more | |||||||
Phase 3 | 2,492 | OM/HCTZ | scephoyhdi(euuufxouyu) = ctghvqgval fzgksdfxbi (eeruqcsexd ) View more | Positive | 01 Jun 2010 | ||
Not Applicable | - | 61 | osurvxspas(fduhbxgnmt) = kuupswugoc saekygxdux (inakypgfoc ) View more | Positive | 01 Jun 2010 | ||
osurvxspas(fduhbxgnmt) = wnlnelgbom saekygxdux (inakypgfoc ) View more | |||||||
Not Applicable | - | - | ijopupelyg(ityytqsnpx) = pfkeemtpxh lzrwcbldid (cpskstjvoe, 9.3) View more | Positive | 01 Jun 2010 | ||
ijopupelyg(ityytqsnpx) = dxagctllos lzrwcbldid (cpskstjvoe, 7.5) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free